Papillophlebitis: Treatment of Vision Loss Due To Subretinal Fluid with Intravitreal Ranibizumab

Creative Commons License

GÜNGÖR İ., Konuk G. E., Süllü Y., Arıtürk N.

NEURO-OPHTHALMOLOGY, vol.38, no.6, pp.336-339, 2014 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 6
  • Publication Date: 2014
  • Doi Number: 10.3109/01658107.2014.954293
  • Journal Name: NEURO-OPHTHALMOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.336-339
  • Keywords: Anti-VEGF, central retinal vein occlusion, macular oedema, papillophlebitis, ranibizumab, MACULAR EDEMA, TRIAMCINOLONE ACETONIDE, BEVACIZUMAB
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

There are no specific treatment protocols for papillophlebitis, which is basically a central retinal vein occlusion (CRVO) occurring in young adults. The present report is that of a 14-year-old girl, who presented with blurred vision in her right eye. Although her visual acuity (VA) was initially 20/20, there were venous engorgements, blurry disc margins, and a substantial collection of subretinal fluid. She was diagnosed with papillophlebitis. When, 2 weeks later, her VA had decreased to 20/200, she was administered intravitreally injected ranibizumab. One week post-injection, her VA had returned to normal (20/20) and the subretinal fluid had diminished markedly. Intravitreal ranibizumab injection appears to be an effective treatment modality for this condition.